A Phase II Study of Weekly Paclitaxel(Taxol)and 24-Hour Infusion High-Dose 5-Fluorouracil and Leucovorin(HDFL)in the Treatment Locally Advanced and Recurrent/Metastatic Gastric Cancers
In the treatment of metastatic breast cancer, paclitaxel followed by weekly HDFL has been
shown to have a 55% response rate in anthracycline-resistant patient. Recently, regimen
combining paclitaxel and moderately-high-dose 5-FU (1500mg/m2) has had response rate up to
61.5% (including 23%CR) in a small group of gastric cancer patients (8 responders in 13
patients). Thus, the sequential use of weekly paclitaxel followed by weekly HDFL regimen may
become a new generation of chemotherapeutic regimen for the treatment of gastric cancer.
Further study with a larger group of patients and further testing of possible schedules of
administration are warranted.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Ann-Lii Cheng, M.D.,Ph.D.
Department of Oncology, National Taiwan University Hospital
Taiwan: Department of Health